Occurrence, removal, and environmental risks of pharmaceuticals in wastewater treatment plants in south China

Abstract

Five pharmaceuticals were detected in wastewater treatment plants in southern China.

Biological treatment was the most effective process for PhACs removal.

Metoprolol showed negative removal during secondary treatment process.

The pharmaceuticals studied posed a low environmental risk to aquatic ecosystems.

Pharmaceutically active compounds in wastewater released from human consumption have received considerable attention because of their possible risks for aquatic environments. In this study, the occurrence and removal of 10 pharmaceuticals in three municipal wastewater treatment plants in southern China were investigated and the environmental risks they posed were assessed. Nifedipine, atenolol, metoprolol, valsartan and pravastatin were detected in the influent wastewater. The highest average concentration in the influents was observed for metoprolol (164.6 ng/L), followed by valsartan (120.3 ng/L) in August, while median concentrations were higher in November than in August. The total average daily mass loadings of the pharmaceuticals in the three plants were 289.52 mg/d/person, 430.46 mg/d/person and 368.67 mg/d/person, respectively. Elimination in the treatment plants studied was incomplete, with metoprolol levels increasing during biological treatment. Biological treatment was the most effective step for PhACs removal in all of the plants studied. Moreover, the removal of PhACs was observed with higher efficiencies in August than in November. The WWTP equipped with an Unitank process exhibited similar removals of most PhACs as other WWTPs equipped with an anoxic/oxic (A/O) process or various anaerobic-anoxic-oxic (A²/O) process. The environmental risk assessment concluded that all of the single PhAC in the effluents displayed a low risk (RQ<0.1) to the aquatic environments.

Graphical abstract

Keywords

Pharmaceuticals / Wastewater treatment / Pearl River Delta / Occurrence / Removal / Risk assessment

References

[1] Backhaus T, Scholze M, Grimme L H (2000). The single substance and mixture toxicity of quinolones to the bioluminescent bacterium Vibrio fischeri. Aquatic Toxicology (Amsterdam, Netherlands), 49(1-2): 49–61

[2] Behera S K, Kim H W, Oh J E, Park H S (2011). Occurrence and removal of antibiotics, hormones and several other pharmaceuticals in wastewater treatment plants of the largest industrial city of Korea. Science of the Total Environment, 409(20): 4351–4360

[3] Brennan P J, Greenberg G, Miall W E, Thompson S G (1982). Seasonal variation in arterial blood pressure. British Medical Journal (Clinical Research Ed.), 285(6346): 919–923

[4] Göbel A, Thomsen A, McArdell C S, Joss A, Giger W (2005). Occurrence and sorption behavior of sulfonamides, macrolides, and trimethoprim in activated sludge treatment. Environmental Science & Technology, 39(11): 3981–3989

[5] Hernando M D, Mezcua M, Fernández-Alba A R, Barceló D (2006). Environmental risk assessment of pharmaceutical residues in wastewater effluents, surface waters and sediments. Talanta, 69(2): 334–342

[6] Huang Q, Yu Y, Tang C, Zhang K, Cui J, Peng X (2011). Occurrence and behavior of non-steroidal anti-inflammatory drugs and lipid regulators in wastewater and urban river water of the Pearl River Delta, South China. Journal of Environmental Monitoring, 13(4): 855– 863

[7] Huerta-Fontela M, Galceran M T, Ventura F (2011). Occurrence and removal of pharmaceuticals and hormones through drinking water treatment. Water Research, 45(3): 1432–1442

[8] Kasprzyk-Hordern B, Dinsdale R M, Guwy A J (2009). The removal of pharmaceuticals, personal care products, endocrine disruptors and illicit drugs during wastewater treatment and its impact on the quality of receiving waters. Water Research, 43(2): 363–380

[9] Khan S J, Ongerth J E (2002). Estimation of pharmaceutical residues in primary and secondary sewage sludge based on quantities of use and fugacity modelling. Water Science and Technology, 46(3): 105–113

[10] Kosma C I, Lambropoulou D A, Albanis T A (2014). Investigation of PPCPs in wastewater treatment plants in Greece: occurrence, removal and environmental risk assessment. Science of the Total Environment, 466-467(1): 421–438

[11] Lolić A, Paíga P, Santos L H M L, Ramos S, Correia M, Delerue-Matos C (2015). Assessment of non-steroidal anti-inflammatory and analgesic pharmaceuticals in seawaters of North of Portugal: Occurrence and environmental risk. Science of the Total Environment, 508(3): 240–250

[12] Lv M, Sun Q, Hu A, Hou L, Li J, Cai X, Yu C P (2014). Pharmaceuticals and personal care products in a mesoscale subtropical watershed and their application as sewage markers. Journal of Hazardous Materials, 280: 696–705

[13] Papageorgiou M, Kosma C, Lambropoulou D (2016). Seasonal occurrence, removal, mass loading and environmental risk assessment of 55 pharmaceuticals and personal care products in a municipal wastewater treatment plant in Central Greece. Science of the Total Environment, 543(A): 547–569

[14] Peng X, Ou W, Wang C, Wang Z, Huang Q, Jin J, Tan J (2014). Occurrence and ecological potential of pharmaceuticals and personal care products in groundwater and reservoirs in the vicinity of municipal landfills in China. Science of the Total Environment, 490(8): 889–898

[15] Quinn B, Gagné F, Blaise C (2009). Evaluation of the acute, chronic and teratogenic effects of a mixture of eleven pharmaceuticals on the cnidarian, Hydra attenuata. Science of the Total Environment, 407(3): 1072–1079

[16] Radjenović J, Petrović M, Barceló D (2009). Fate and distribution of pharmaceuticals in wastewater and sewage sludge of the conventional activated sludge (CAS) and advanced membrane bioreactor (MBR) treatment. Water Research, 43(3): 831–841

[17] Roberts J, Kumar A, Du J, Hepplewhite C, Ellis D J, Christy A G, Beavis S G (2016). Pharmaceuticals and personal care products (PPCPs) in Australia’s largest inland sewage treatment plant, and its contribution to a major Australian river during high and low flow. Science of the Total Environment, 541(1): 1625–1637

[18] Rosal R, Rodríguez A, Perdigón-Melón J A, Petre A, García-Calvo E, Gómez M J, Agüera A, Fernández-Alba A R (2010). Occurrence of emerging pollutants in urban wastewater and their removal through biological treatment followed by ozonation. Water Research, 44(2 2SI): 578–588

[19] Subedi B, Kannan K (2015). Occurrence and fate of select psychoactive pharmaceuticals and antihypertensives in two wastewater treatment plants in New York State, USA. Science of the Total Environment, 514(5): 273–280

[20] Sui Q, Huang J, Deng S, Chen W, Yu G (2011). Seasonal variation in the occurrence and removal of pharmaceuticals and personal care products in different biological wastewater treatment processes. Environmental Science & Technology, 45(8): 3341–3348

[21] Sun Q, Lv M, Hu A (2014). Seasonal variation in the occurrence and removal of pharmaceuticals and personal care products in a wastewater treatment plant in Xiamen, China. Journal of Hazardous Materials, 277(SI): 69–75

[22] United State Environmental Protection Agency (USEPA) (2007). EPA Method 1694: Pharmaceuticals and Personal Care Products in Water, Soil, Sediment, and Biosolids by HPLC/MS/MS

[23] Verlicchi P, Al Aukidy M, Zambello E (2012). Occurrence of pharmaceutical compounds in urban wastewater: Removal, mass load and environmental risk after a secondary treatment--a review. Science of the Total Environment, 429: 123–155

[24] Verlicchi P, Galletti A, Petrovic M, Barceló D (2010). Hospital effluents as a source of emerging pollutants: An overview of micropollutants and sustainable treatment options. Journal of Hydrology (Amsterdam), 389(3–4): 416–428

[25] Vieno N, Tuhkanen T, Kronberg L (2007). Elimination of pharmaceuticals in sewage treatment plants in Finland. Water Research, 41(5): 1001–1012

[26] Wang J, Zhang L, Wang F, Liu L, Wang H, and the China National Survey of Chronic Kidney Disease Working Group (2014). Prevalence, awareness, treatment, and control of hypertension in China: Results from a national survey. American Journal of Hypertension, 27(11): 1355–1361

[27] Yan Q, Gao X, Chen Y P, Peng X Y, Zhang Y X, Gan X M, Zi C F, Guo J S (2014a). Occurrence, fate and ecotoxicological assessment of pharmaceutically active compounds in wastewater and sludge from wastewater treatment plants in Chongqing, the Three Gorges Reservoir Area. Science of the Total Environment, 470-471(2): 618–630

[28] Yan Q, Gao X, Huang L, Gan X M, Zhang Y X, Chen Y P, Peng X Y, Guo J S (2014a). Occurrence and fate of pharmaceutically active compounds in the largest municipal wastewater treatment plant in Southwest China: Mass balance analysis and consumption back-calculated model. Chemosphere, 99(3): 160–170

[29] Yuan X, Qiang Z, Ben W, Zhu B, Qu J (2015). Distribution, mass load and environmental impact of multiple-class pharmaceuticals in conventional and upgraded municipal wastewater treatment plants in East China. Environmental Science. Processes & Impacts, 17(3): 596–605

RIGHTS & PERMISSIONS

Higher Education Press and Springer-Verlag GmbH Germany, part of Springer Nature